Automated storage systems and large-scale freezers can be challenging for conventional fire protection systems. Instead, an oxygen reduction system (ORS) could be a suitable option. In an ORS the design oxygen concentration is the key parameter for the level of protection achieved by the system. However, current methods for determining this concentration yield varying results and either require large and complex test setups or arrive at overly optimistic levels for protection. In this paper, an experimental method for using the controlled atmosphere cone calorimeter (CACC) to find the limiting oxygen concentration at extinction (LOCext) is proposed. The results from the CACC showed good agreement with limiting oxygen concentrations (LOC) determined by large-scale; indicating that the CACC could serve as a cost-effective alternative for determining the LOC of ordinary combustibles for ORS applications. Furthermore, thermal analysis and experiments using both nitrogen and carbon dioxide highlights that the thermal properties of the diluent gas, rather than oxygen displacement and chemical quenching, are the primary factors influencing the LOC. Hence, the findings in this paper increase the understanding of ORS systems and offer a way to determine the LOC for ORS based on small-scale testing.
Current music recommendation systems often lack transparency, preventing users from understanding the recommendations or effectively steering the algorithm. We present HUMMUS, an interactive collaborative music sequential recommender system that applies Giorgia Lupi's Data Humanism principles to combine algorithmic transparency with human-centered design. HUMMUS visualizes songs as flowers, where petals represent audio features, and connecting lines reveal recommendation relationships. Real-time voting mechanisms during natural pauses in social interaction enable collaborative decision-making between humans and recommendation algorithms. Our mixed-methods evaluation, involving 19 participants, demonstrates that humanistic design principles enhance transparency, user engagement, and collaborative decision-making while maintaining the quality of recommendations. This work contributes to the intersection of critical visualization and explainable AI by demonstrating how Data Humanism can guide human-centered recommendation systems.
The growing importance of digitalization in business also has its impact on automation. In this section, we will put this into the perspective of significant market drivers, and different views on aspects of automation, across the industrial value chain, or along the automation lifecycle. Key trends in digitalization are having an impact on automation. Making data available for more applications through the industrial Internet of Things (industrial IoT) and cyber physical systems will be covered. Such systems expand the traditional automation stack with more advanced (wired and wireless) communication technologies, and the computing power and storage available in a cloud further extends capacity for additional functionality. An important use of data is artificial intelligence. We will cover AI's impact on the industry, and how it plays into the automation functionality. The context of the data and its analysis is brought together in the concept of the digital twin that is covered as well. The availability of these technologies, from IoT to AI, allows for an evolution of automation toward more autonomous systems. Autonomy is today mostly seen in vehicles, we will put it into the context of the industrial automation system and will show how systems (among other robots) will become more autonomous, and will get the capability to collaborate. This will open a whole new range of applications, enabled by a bright future of automation.
The field of additive manufacturing (AM) has been continuously growing for more than 30 years. This chapter describes a range of applications for AM. It highlights the development along the complete value chain including application needs, part design, and production.
e13647 Background: Oncology-relevant measures of disease and treatment support earlier detection, accelerated drug development, and inform treatment pathways. To advance access to transformative treatments for people with cancer, especially those for early-stage cancers where medical intervention has the greatest opportunity to impact the course of the disease, the cancer community identified seven principles that support the evolution of value assessment frameworks. Here we summarize the five key principles. Methods: A group of 24 cancer community experts (9 oncologists, 6 patient advocacy leaders, 1 former regulator, 6 former payers, and 4 health economists) from 14 countries came together to discuss and build consensus on oncology-relevant value principles. Over five months, the expert group engaged via surveys, virtual discussion panels, and interviews. Results: The expert group developed seven consensus principles covering two areas: oncology-relevant endpoints to assess the value of treatments; and additional important value components and how they can be integrated into value assessments. The key 5 principles were oncology-relevant endpoints assessing clinical effectiveness, including the following three items. 1) Consider oncology-relevant endpoints, other than Overall Survival (OS), with intrinsic value for decision-making e.g., Event-, Disease-, or Relapse-Free Survival. 2) Continue to build evidence for endpoints that indicate treatment efficacy earlier e.g., pathologic Complete Response. 3) Develop evidence for the next generation of predictive measures that detect and monitor disease, e.g., circulating tumor DNA and Minimal Residual Disease. Additional value components supporting patient access include the following two items. 1) Use managed entry (type of access) agreements supported by ongoing real world evidence collection to help address decision-maker (regulator and Health Technology Assessment body) evidence needs. 2) Routinely use Patient Reported Outcomes (PROs) in value assessments. Conclusions: To achieve the common goal of all cancer community stakeholders—improved outcomes for people with cancer—collaboration across the cancer community is essential to define how value is assessed, especially for early-stage cancer treatments. This is particularly important since mature OS data is not always available during initial decision-making, and decision-makers need to evolve which are the most appropriate endpoints. This supports measuring clinical impact, but also broader social, financial and ethical impact for patients, caregivers, healthcare systems, society, and the economy (not considered in this abstract). To achieve these goals, the expert group recommends: 1) increasing awareness and systematically engaging people with cancer in value assessments, 2) leveraging PROs in those assessments, and 3) further validation in clinical trials of oncology-relevant endpoints that could provide an earlier indication of clinical outcomes.